Common Contracts
9 similar null contracts by Akero Therapeutics, Inc., Annexon, Inc., Atmos Energy Corp, others
Annexon, Inc. 25,035,000 Shares of Common Stock, par value $0.001 per share Pre-Funded Warrants to Purchase 18,379,861 Shares of Common Stock Underwriting AgreementAnnexon, Inc. • December 21st, 2023 • Pharmaceutical preparations • New York
Annexon, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom Jefferies LLC (“Jefferies”) and Cowen and Company, LLC (“TD Cowen”) are acting as representatives (the “Representatives”), (i) an aggregate of 25,035,000 shares (the “Offered Shares”) of common stock, par value $0.001 per share (“Common Stock”) and (ii) pre-funded warrants to purchase 18,379,861 shares of Common Stock (the “Pre-Funded Warrants”) of the Company; the Offered Shares and the Pre-Funded Warrants to be sold by the Company are collectively referred to as the “Offered Securities”. As used herein, “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Offered Securities are referred to herein as the “Stock”.
Akero Therapeutics, Inc. 5,238,500 Shares of Common Stock, par value $0.0001 per share Underwriting AgreementAkero Therapeutics, Inc. • May 17th, 2023 • Pharmaceutical preparations • New York
Akero Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 5,238,500 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Shares”). The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. To the extent there are no additional Underwriters listed on Schedule 1 other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriters shall mean either the singular or plural as the context requires.
GRAFTECH INTERNATIONAL LTD. 8,500,000 Shares of Common Stock Underwriting AgreementGraftech International LTD • December 17th, 2020 • Electrical industrial apparatus • New York
Brookfield BBP (Canada) L.P., Brookfield BBP Canada Holdings Inc., BPE IV (Non-Cdn) GP LP and BCP IV GrafTech Holdings LP (collectively, the “Selling Stockholders”), shareholders of GrafTech International Ltd., a Delaware corporation (the “Company”), propose to sell to you (the “Underwriter”) an aggregate of 8,500,000 shares of common stock, par value $0.01 per share (the “Common Stock”), of the Company (the “Shares”).
GUARDANT HEALTH, INC. 7,000,000 Shares of Common Stock, par value $0.00001 per share Underwriting AgreementGuardant Health, Inc. • October 13th, 2020 • Services-medical laboratories • New York
Certain stockholders named in Schedule 2 hereto (the “Selling Stockholders”) of Guardant Health, Inc., a Delaware corporation (the “Company”), propose to sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 7,000,000 shares of common stock, par value $0.00001 per share (“Common Stock”), of the Company (the “Underwritten Shares”). In addition, the Selling Stockholders propose to sell, at the option of the Underwriters, up to an additional 700,000 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. To the extent there are no additional Underwriters listed on Schedule 1 other than you, the term Representatives as used herein shall mean you, as Underwriter, a
CERIDIAN HCM HOLDING INC. 7,717,347 Shares of Common Stock Underwriting AgreementCeridian HCM Holding Inc. • August 28th, 2020 • Services-prepackaged software • New York
Certain stockholders named in Schedule 2 hereto (the “Selling Stockholders”) of Ceridian HCM Holding Inc., a Delaware corporation (the “Company”), propose to sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”) an aggregate of 7,717,347 shares of common stock, par value $0.01 per share, of the Company (collectively, the “Shares”). The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
ATMOS ENERGY CORPORATION 4,558,404 Shares of Common Stock Underwriting AgreementAtmos Energy Corp • December 1st, 2017 • Natural gas distribution • New York
Atmos Energy Corporation, a Texas and Virginia corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule I hereto (the “Underwriters”) an aggregate of 4,558,404 shares of common stock, no par value, of the Company (the “Shares”). The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
RETAIL PROPERTIES OF AMERICA, INC. $250,000,000 4.00% Senior Notes Due 2025 Underwriting AgreementRetail Properties of America, Inc. • March 12th, 2015 • Real estate investment trusts • New York
Retail Properties of America, Inc., a Maryland corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of $250,000,000 principal amount of the 4.00% Senior Notes due 2025 of the Company (the “Securities”). The Securities will be issued pursuant to an Indenture to be dated as of March 12, 2015 (the “Base Indenture”) between the Company and U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture to be dated as of March 12, 2015 by and between the Company and the Trustee (the “Supplemental Indenture,” and together with the Base Indenture, the “Indenture”).
SYNOVUS FINANCIAL CORP. $300,000,000 7.875% Senior Notes due 2019 Underwriting AgreementSynovus Financial Corp • February 13th, 2012 • National commercial banks • New York
Synovus Financial Corp., a Georgia corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of $300,000,000 in principal amount of its 7.875% Senior Notes due 2019, to be issued under an indenture, to be dated as of February 13, 2012 (the “Indenture”) between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”) (the “Securities”).
UIL HOLDINGS CORPORATION 4.625% Notes due 2020 Underwriting AgreementUil Holdings Corp • October 7th, 2010 • Electric services • New York
The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Banc of America Securities LLC toll-free at 1-800-294-1322, J.P. Morgan Securities LLC collect at 1-212-834-4533, or Morgan Stanley & Co. Incorporated toll-free at 1-866-718-1649.
